Potassium and risk of type 2 diabetes

Expert Review of Endocrinology and Metabolism

Volumn 6, Issue 5, 2011, Pages 665-672

  Chatterjee, Ranee ^a   Yeh, Hsin Chieh ^b   Edelman, David ^a   Brancati, Frederick ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antihypertensives affecting potassium; diabetes risk; dietary potassium; serum potassium

Indexed keywords

CANDESARTAN; CHLORTALIDONE; GLUCOSE; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; POTASSIUM; RAMIPRIL; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

ARTICLE; CLINICAL TRIAL (TOPIC); DIETARY INTAKE; DRUG EFFECT; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; HYPOKALEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; POTASSIUM BLOOD LEVEL; POTASSIUM INTAKE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 80052502002     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/eem.11.60     Document Type: Article

References (52)

1. Dall T, Mann SE, Zhang Y et al. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 31(3), 596-615 (2008).
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27(5), 1047-1053 (2004). (Pubitemid 38579764)
3. Stern, MP, Haffner SM. Body fat distribution and hyperinsulinemia as risk factors for diabetes and cardiovascular disease. Arteriosclerosis 6(2), 123-130 (1986). (Pubitemid 16024120)
4. Martini LA, Catania AS, Ferreira SR. Role of vitamins and minerals in prevention and management of Type 2 diabetes mellitus. Nutr. Rev. 68(6), 341-354 (2010).
5. Hectors TL, Vanparys C, van der Ven K et al. Environmental pollutants and Type 2 diabetes: a review of mechanisms that can disrupt b cell function. Diabetologia 54(6), 1273-1290 (2011).
6. Grant RW, Moore AF, Florez JC. Genetic architecture of Type 2 diabetes: recent progress and clinical implications. Diabetes Care 32(6), 1107-1114 (2009).
7. Corry DB, Tuck ML. The effect of aldosterone on glucose metabolism. Curr. Hypertens. Rep. 5(2), 106-109 (2003). (Pubitemid 38898939)
8. Conn JW. Hypertension, the potassium ion and impaired carbohydrate tolerance. N. Engl. J. Med. 273(21) 1135-1143 (1965).
9. Carter BL, Einhorn PT, Brands M et al. Thiazide-induced dysglycemia: call for research from a working group from the National Heart, Lung, and Blood institute. Hypertension 52, 30-36 (2008).
10. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 48(2), 219-224 (2006). (Pubitemid 44309815)
11. Rapoport MI, Hurd HF. Thiazide-induced glucose intolerance treated with potassium. Arch. Intern. Med. 113, 405-408 (1964).
12. Jackson JH, Sobolski J, Krienke R, Wong KS, Frech-Tamas F, Nightengale B. Blood pressure control and pharmacotherapy patterns in the United States before and after the release of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) guidelines. J. Am. Board Fam. Med. 21(6), 512-521 (2008).
13. Chatterjee R, Yeh HC, Shafi T et al. Serum and dietary potassium and risk of incident Type 2 diabetes mellitus: the Atherosclerosis Risk in Communities (ARIC) study. Arch. Intern. Med. 170, 1745-1751 (2010).
14. Heianza Y, Hara S, Arase Y et al. Low serum potassium levels and risk of Type 2 diabetes: the Toranomon Hospital Health Management Center Study 1 (TOPICS1). Diabetologia 54(4), 762-766 (2011).
15. Evans KJ, Greenberg A. Hyperkalemia: a review. J. Intensive Care Med. 20(5), 272-290 (2005). (Pubitemid 43080638)
16. Panel on Dietary Reference Intakes for Electrolytes and Water; The Standing Committee on the Scientific Evaluation of Dietary Reference Intakes; National Academy of Sciences. Chapter 5: Potassium. In: Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate. The National Academies Press, Washington DC, USA, 186-268 (2004).
17. Gorden P. Glucose intolerance with hypokalemia. Failure of short-term potassium depletion in normal subjects to reproduce the glucose and insulin abnormalities of clinical hypokalemia. Diabetes 22(7), 544-551 (1973).
18. Helderman JH, Elahi D, Andersen DK, et al. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes 32(2), 106-111 (1983). (Pubitemid 13180341)
19. Rowe JW, Tobin JD, Rosa RM, Andres R. Effect of experimental potassium deficiency on glucose and insulin metabolism. Metabolism 29(6), 498-502 (1980). (Pubitemid 10123237)
20. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288(23), 2981-2997 (2002).
21. Taylor EN, Hu FB, Curhan GC. Antihypertensive medications and the risk of incident Type 2 diabetes. Diabetes Care 29(5), 1065-1070 (2006). (Pubitemid 44115245)
22. Burke TA, Sturkenboom MC, Ohman-Strickland PA, Wentworth CE, Rhoads GG. The effect of antihypertensive drugs and drug combinations on the incidence of new-onset Type 2 diabetes mellitus. Pharmacoepidemiol. Drug Saf. 16(9), 979-987 (2007). (Pubitemid 47422846)
23. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for Type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N. Engl. J. Med. 342(13), 905-912 (2000). (Pubitemid 30177050)
24. Donahue RP, Abbott RD, Wilson PW. Effect of diuretic use on the development of diabetes mellitus. The Framingham study. Horm. Metab. Res. Suppl. 22, 46-48 (1990). (Pubitemid 20207579)
25. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369(9557), 201-207 (2007). (Pubitemid 46111014)
26. Shafi T, Appel LJ, Miller ER, Klag MJ, Parekh RS. Changes in serum potassium mediate thiazide-induced diabetes Hypertension 52, 1022-1029 (2008).
27. Eriksson JW, Jansson PA, Carlberg B et al. Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the Mechanisms for the Diabetes Preventing Effect of Candesartan (MEDICA) study. Hypertension 52(6), 1030-1037 (2008).
28. Bakris G, Molitch M, Hewkin A et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 29(12), 2592-2597 (2006). (Pubitemid 44912184)
29. Bosch J, Yusuf S, Gerstein HC et al. Effect of ramipril on the incidence of diabetes. N. Engl. J. Med. 355(15), 1551-1562 (2006). (Pubitemid 44550032)
30. McMurray JJ, Holman RR, Haffner SM et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N. Engl. J. Med. 362(16), 1477-1479 (2010).
31. Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin. J. Am. Soc. Nephrol. 5(3), 531-548 (2010).
32. Barzilay JI, Davis BR, Cutler JA et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch. Intern. Med. 166(20), 2191-2201 (2006). (Pubitemid 44748765)
33. Andraws R, Brown DL. Effect of inhibition of the renin-angiotensin system on development of Type 2 diabetes mellitus (meta-analysis of randomized trials). Am. J. Cardiol. 99(7), 1006-1012 (2007). (Pubitemid 46483294)
34. Tocci G, Paneni F, Palano F et al. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials. Am. J. Hypertens. 24(5), 582-590 (2011).
35. McGuire DK, Winterfield JR, Rytlewski JA et al. Blocking the renin-angiotensin- aldosterone system to prevent diabetes mellitus. Diab. Vasc. Dis. Res. 5(1), 59-66 (2008). (Pubitemid 351507348)
36. Hershon KS. Mechanistic and clinical aspects of renin-angiotensin- aldosterone system (RAAS) blockade in the prevention of diabetes and cardiovascular disease. Endocr. Pract. 17(3), 430-440 (2011).
37. Santoro D, Natali A, Palombo C et al. Effects of chronic angiotensin converting enzyme inhibition on glucose tolerance and insulin sensitivity in essential hypertension. Hypertension 20(2), 181-191 (1992).
38. Chatterjee R, Yeh HC, Shafi T et al. Serum potassium and the racial disparity in diabetes risk: the Atherosclerosis Risk in Communities (ARIC) Study. Am. J. Clin. Nutr. 93(5), 1087-1091 (2011).
39. Bingham SA, Day NE. Using biochemical markers to assess the validity of prospective dietary assessment methods and the effect of energy adjustment. Am. J. Clin. Nutr. 65(4 Suppl.), 1130S-1137S (1997). (Pubitemid 27152574)
40. Liu K, Slattery M, Jacobs D Jr et al. A study of the reliability and comparative validity of the CARDIA dietary history. Ethn. Dis. 4(1), 15-27 (1994).
41. Tasevska N, Runswick SA, Bingham SA, Urinary potassium is as reliable as urinary nitrogen for use as a recovery biomarker in dietary studies of free living individuals. J. Nutr. 136(5), 1334-1340 (2006).
42. Bingham SA, Gill C, Welch A et al. Validation of dietary assessment methods in the UK arm of EPIC using weighed records, and 24-hour urinary nitrogen and potassium and serum vitamin C and carotenoids as biomarkers. Int. J. Epidemiol. 26(Suppl. 1), S137-S151 (1997). (Pubitemid 27129698)
43. Turban S, Miller ER, Ange B, Appel LJ. Racial differences in urinary potassium excretion. J. Am. Soc. Nephrol. 19(7), 1396-1402 (2008).
44. Conlin PR, Chow D, Miller ER et al. The effect of dietary patterns on blood pressure control in hypertensive patients: results from the Dietary Approaches to Stop Hypertension (DASH) trial. Am. J. Hypertens. 13(9), 949-955 (2000).
45. Hu G, Jousilahti P, Peltonen M, Lindström J, Tuomilehto J. Urinary sodium and potassium excretion and the risk of Type 2 diabetes: a prospective study in Finland. Diabetologia 48(8), 1477-1483 (2005). (Pubitemid 41175499)
46. Colditz, GA, Manson JE, Stampfer MJ, Rosner B, Willett WC, Speizer FE. Diet and risk of clinical diabetes in women. Am. J. Clin. Nutr. 55(5), 1018-1023 (1992).
47. Liese AD, Nichols M, Sun X et al. Adherence to the DASH diet is inversely associated with incidence of Type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes Care 32(8), 1434-1436 (2009).
48. Blumenthal JA, Babyak MA, Sherwood A et al. Effects of the dietary approaches to stop hypertension diet alone and in combination with exercise and caloric restriction on insulin sensitivity and lipids. Hypertension 55(5), 1199-1205 (2010).
49. Carter P, Gray LJ, Troughton J, Khunti K, Davies MJ. Fruit and vegetable intake and incidence of Type 2 diabetes mellitus: systematic review and meta-analysis. BMJ 341, c4229 (2010).
50. Been LF, Ralhan S, Wander GS et al. Variants in KCNQ1 increase Type II diabetes susceptibility in South Asians: a study of 3,310 subjects from India and the US. BMC Med. Genet. 12, 18 (2011).
51. Zhou JB, Yang JK, Zhao L, Xin Z. Variants in KCNQ1, AP3S1, MAN2A1, and ALDH7A1 and the risk of Type 2 diabetes in the Chinese Northern Han population: a case-control study and meta-analysis. Med. Sci. Monit. 16(6), BR179-BR183 (2010).
52. International Diabetes Federation. Position statement - diabetes and obesity www.idf.org/position-statement-diabetes-and-obesity